But the mRNA expression of different hepatic genes asserted that the inhibition in the overall NAFLD by pyruvate was not due to the decreased expression of lipogenic genes including SREBP-1c, FASN, and SCD-1 but due to the attenuation of the inflammatory markers including the secretory level of IL-1β and IL-6. This evidence concerns the gene FASN and metabolic dysfunction-associated steatotic liver disease.